AngioDynamics Awarded $74.9 Million in Case Against biolitec AG

AngioDynamics Awarded $74.9 Million in Case Against biolitec AG

ALBANY, N.Y., March 20, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO),
a leading provider of innovative, minimally invasive medical devices for
vascular access, surgery, peripheral vascular disease and oncology, today
announced a recent court action in its legal case against biolitec AG.

On March 18, 2014, the United States District Court for the District of
Massachusetts entered a judgment awarding AngioDynamics $74.9 million in
damages based on AngioDynamics' claims that biolitec AG, Biomed Technology
Holdings Limited and Wolfgang Neuberger tortiously interfered with its U.S.
subsidiary, biolitec Inc.'s, contractual obligations. The judgment is also
based on claims of piercing the biolitec's corporate veil, fraudulent
transfers and violations of Massachusetts's Unfair Business Practices Act.

The dispute originally began when AngioDynamics asserted biolitec Inc.
breached a contractual agreement to defend and indemnify AngioDynamics against
patent infringement claims by third parties arising out of the use of laser
vein ablation products supplied by biolitec.

"We are pleased with the court's decision," said AngioDynamics President and
Chief Executive Officer Joseph M. DeVivo. "The judgment was based on the
defendant's refusal to cooperate in their discovery obligations in the
Massachusetts court, just as biolitec originally failed to live up to its
obligation to indemnify us, hurting our business as we defended ourselves
against infringement claims concerning the distribution of their products. We
will continue to vigorously pursue this litigation until we recover our
damages, however long it takes."

About AngioDynamics

AngioDynamics Inc. is a leading provider of innovative, minimally invasive
medical devices used by professional healthcare providers for vascular access,
surgery, peripheral vascular disease and oncology. AngioDynamics' diverse
product lines include market-leading ablation systems, fluid management
systems, vascular access products, angiographic products and accessories,
angioplasty products, drainage products, thrombolytic products and venous
products. More information is available at


AngioDynamics and the AngioDynamics logo are trademarks and/or registered
trademarks of AngioDynamics Inc., an affiliate or a subsidiary.

Safe Harbor

This release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements regarding
AngioDynamics' expected future financial position, results of operations, cash
flows, business strategy, budgets, projected costs, capital expenditures,
products, competitive positions, growth opportunities, plans and objectives of
management for future operations, as well as statements that include the words
such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes,"
"seeks," "estimates," "optimistic," or variations of such words and similar
expressions, are forward-looking statements. These forward looking statements
are not guarantees of future performance and are subject to risks and
uncertainties. Investors are cautioned that actual events or results may
differ from AngioDynamics' expectations. Factors that may affect the actual
results achieved by AngioDynamics include, without limitation, the ability of
AngioDynamics to develop its existing and new products, technological advances
and patents attained by competitors, future actions by the FDA or other
regulatory agencies, domestic and foreign health care reforms and government
regulations, results of pending or future clinical trials, overall economic
conditions, the results of on-going litigation, the effects of economic,
credit and capital market conditions, general market conditions, market
acceptance, foreign currency exchange rate fluctuations, the effects on
pricing from group purchasing organizations and competition, the ability of
AngioDynamics to integrate purchased businesses, including Navilyst Medical
and its products, R&D capabilities, infrastructure and employees as well as
the risk factors listed from time to time in AngioDynamics' SEC filings,
including but not limited to its Annual Report on Form 10-K for the year ended
May 31, 2013. AngioDynamics does not assume any obligation to publicly update
or revise any forward-looking statements for any reason.

CONTACT: Company Contact:
         AngioDynamics, Inc.
         Mark Frost, CFO
         (800) 772-6446 x1981
         Investor Relations Contacts:
         EVC Group, Inc.
         Michael Polyviou/Robert Jones
         (212) 850-6020; (646) 201-5447;
         Media Contact:
         EVC Group, Inc.
         Dave Schemelia
         (646) 201-5431
Press spacebar to pause and continue. Press esc to stop.